Adoption and diffusion of SGLT2 inhibitors among cardiologists in medicare part D, 2019-2023: a provider-level observational study.

Kim T, Ryan D, Joseph J

Open source

DOI
10.1186/s12872-026-06460-x
Published
2026 Aug 13
Container
BMC cardiovascular disorders
Publisher
Not recorded
Open access
unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1186/s12872-026-06460-x,
  title = {Adoption and diffusion of SGLT2 inhibitors among cardiologists in medicare part D, 2019-2023: a provider-level observational study.},
  author = {Kim T and Ryan D and Joseph J},
  year = {2026},
  journal = {BMC cardiovascular disorders},
  doi = {10.1186/s12872-026-06460-x},
  url = {https://doi.org/10.1186/s12872-026-06460-x}
}

RIS

TY  - JOUR
TI  - Adoption and diffusion of SGLT2 inhibitors among cardiologists in medicare part D, 2019-2023: a provider-level observational study.
AU  - Kim T
AU  - Ryan D
AU  - Joseph J
PY  - 2026
JO  - BMC cardiovascular disorders
DO  - 10.1186/s12872-026-06460-x
UR  - https://doi.org/10.1186/s12872-026-06460-x
ER  - 

APA

T, K., D, R., & J, J. (2026). Adoption and diffusion of SGLT2 inhibitors among cardiologists in medicare part D, 2019-2023: a provider-level observational study.. BMC cardiovascular disorders. https://doi.org/10.1186/s12872-026-06460-x

Source records